Vascular Discovery 2026 Scientific Sessions  /  09. Plenary Session 3: Advancing Cardiometabolic Care: From GLP-1 to SGLT2 and Beyond  /  TBD
Logo

American Heart Association

  1
  0

Final ID:

TBD

  • Pandey, Ambarish  ( UT Southwestern Medical Center , Dallas , Texas , United States )
    • Author Disclosures:
    Ambarish Pandey: DO have relevant financial relationships ; Advisor:Tricog Health Inc, Lilly, Rivus, Roche Diagnostics, Axon Therapies,  Edward Lifesciences, Science37, Novo Nordisk, Bayer, Medical AI, Astra Zeneca, Baylor Scott and White Research Institute, Boehringer Ingelheim, iRhythm Technologies, Tourmaline Bio, Merck, Sarfez Pharmaceuticals, Ultromics, Kardigan, Boehringer Ingelheim, Tenax Pharma, Alnylam, Abbott, Kieele Health, Anumana, Acorai, Novartis, Antlia Biosciences.:Active (exists now) ; Speaker:Boehringer Ingelheim, Bayer, Astra Zeneca:Active (exists now)
Meeting Info:

Vascular Discovery 2026 Scientific Sessions

2026

Bellevue, Washington

Session Info:

09. Plenary Session 3: Advancing Cardiometabolic Care: From GLP-1 to SGLT2 and Beyond

Friday, 05/15/2026 , 08:00AM - 09:30AM

Oral

More abstracts on this topic:
Pulmonary Vascular Disease in the GLP-1 Era: Metabolic Modulation Meets Vascular Remodeling

Leopold Jane

The microvasculature is at the heart of HFpEF

Fish Jason

More abstracts from these authors:
Decoding a Silent Threat: Uncovering Aldosterone's Impact on Hypertension and Cardiovascular Morbidity

Pandey Ambarish

Neo’s Quest: Leveraging informatics to achieve GDMT for heart failure

Pandey Ambarish, Desai Akshay

You have to be authorized to contact abstract author. Please, Login
Not Available